AVALYN PHARMA INC (AVLN) — insider trading
Health Care · NASDAQ
AVALYN PHARMA INC (AVLN) has 42 reported SEC Form 4 insider transactions in our data, including 4 open-market purchases among the most recent 42 (latest 2026-05-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative (derivative) | 377,948 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative (derivative) | 225,843 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative (derivative) | 872,868 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative (derivative) | 80,291 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative (derivative) | 727,585 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative | 377,948 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative | 225,843 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative | 872,868 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative | 80,291 | — | — | Form 4 |
| 2026-05-01 | FMR LLC | 10% owner, Other | Conversion of derivative | 727,585 | — | — | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Conversion of derivative (derivative) | 12,558,081 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Conversion of derivative (derivative) | 5,587,603 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Conversion of derivative (derivative) | 25,899,284 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Conversion of derivative (derivative) | 1,986,369 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Conversion of derivative (derivative) | 18,000,000 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Open-market purchase | 555,555 | $18.00 | $10.00M | Form 4 |
| 2026-05-01 | Novo Holdings A/S | 10% owner | Conversion of derivative | 3,327,734 | — | — | Form 4 |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% owner | Conversion of derivative (derivative) | 4,060,259 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% owner | Conversion of derivative (derivative) | 20,482,289 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10% owner | Conversion of derivative | 1,275,486 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative (derivative) | 9,418,560 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative (derivative) | 6,827,429 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative (derivative) | 9,418,561 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative (derivative) | 27,309,719 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Open-market purchase | 277,777 | $18.00 | $5.00M | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative | 489,486 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative | 354,824 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Open-market purchase | 277,778 | $18.00 | $5.00M | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative | 489,486 | — | — | Form 4 |
| 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC; George Simeon | 10% owner | Conversion of derivative | 1,419,298 | — | — | Form 4 |
| 2026-05-01 | Carroll Jill | Director | Conversion of derivative (derivative) | 9,418,561 | — | — | Form 4 |
| 2026-05-01 | Carroll Jill | Director | Conversion of derivative (derivative) | 27,309,719 | — | — | Form 4 |
| 2026-05-01 | Carroll Jill | Director | Open-market purchase | 277,778 | $18.00 | $5.00M | Form 4 |
| 2026-05-01 | Carroll Jill | Director | Conversion of derivative | 489,486 | — | — | Form 4 |
| 2026-05-01 | Carroll Jill | Director | Conversion of derivative | 1,419,298 | — | — | Form 4 |
| 2026-04-30 | Carlson Douglas R | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 211,975 | $0.00 | $0 | Form 4 |
| 2026-04-29 | Golden Adam H. | Officer (General Counsel) | Grant / award / vesting (derivative) | 254,891 | $0.00 | $0 | Form 4 |
| 2026-04-29 | Lazarus Howard | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 211,975 | $0.00 | $0 | Form 4 |
| 2026-04-29 | Haviland Kate | Director | Grant / award / vesting (derivative) | 26,978 | $0.00 | $0 | Form 4 |
| 2026-04-29 | Rhodes Melissa | Officer (Chief Operating Officer) | Grant / award / vesting (derivative) | 211,975 | $0.00 | $0 | Form 4 |
| 2026-04-29 | Turner Heather D | Director | Grant / award / vesting (derivative) | 26,978 | $0.00 | $0 | Form 4 |
| 2026-04-29 | Congleton Jon | Director | Grant / award / vesting (derivative) | 26,978 | $0.00 | $0 | Form 4 |
Ask the chat about AVLN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: AVALYN PHARMA INC (AVLN).
Last updated 2026-05-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.